TSOI — Therapeutic Solutions International Income Statement
0.000.00%
- $1.02m
- $2.28m
- $0.10m
Annual income statement for Therapeutic Solutions International, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.028 | 0.063 | 0.146 | 0.207 | 0.099 |
Cost of Revenue | |||||
Gross Profit | 0.024 | 0.05 | 0.103 | 0.127 | 0.062 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.07 | 1.91 | 2.45 | 3.49 | 1.92 |
Operating Profit | -1.04 | -1.85 | -2.3 | -3.28 | -1.82 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.7 | -2.2 | -2.96 | -3.88 | -2.22 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.7 | -2.2 | -2.96 | -3.88 | -2.22 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1.7 | -2.2 | -2.96 | -3.81 | -2.17 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.7 | -2.2 | -2.96 | -3.81 | -2.17 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.001 | -0.001 | -0.001 | -0.002 | -0.001 |